Citations

Clear

273 citation(s) found for "Simone, N De".

Cardiac Resynchronization Therapy, Remodeling, and Outcome in Patients With Amyloid Transthyretin Cardiomyopathy
Aimo, Alberto , Nesti, Martina , Vergaro, Giuseppe , Killu, Ammar M. , Bampatsias, Dimitrios, Tomasoni, Daniela , Forleo, Cinzia , Musca, Francesco , Rosenthal, Julie , Teruya, Sergio , Tameze, Mariel S., Nicolai, Alessio, Saro, Riccardo , Fico, Vera , Frau, Elisa, Longhi, Simone , Chimenti, Cristina , Metra, Marco , Grogan, Martha , Perfetto, Federico , Merlo, Marco , Maurer, Mathew S. , Masri, Ahmad , Rosenthal, Julie L , Teruya, Sergio L , Al Shakarchi, Nader , Castiglione, Vincenzo , Porcari, Aldostefano , Fico, Vera , Guaricci, Andrea I , Tini, Giacomo , Cipriani, Alberto , Longhi, Simone , Chimenti, Cristina , Metra, Marco , Grogan, Martha , Perfetto, Federico , Cappelli, Francesco , Merlo, Marco , Sinagra, Gianfranco , Maurer, Mathew S , Masri, Ahmad , Emdin, Michele , Serenelli, Matteo , Al-Shakarchi, Nader , Castiglione, Vincenzo , Panichella, Giorgia , Porcari, Aldostefano , Sinigiani, Giulio , Frau, Elisa, Matar, Reem , Musumeci, Beatrice

Mayo Clinic

Journal of the American Heart Association | November 12, 2025 | Volume: 14 | Issue: 22 | Pages: No page available

10.1161/jaha.125.043049 | PMID 41220156 Get It

Background Transthyretin amyloid cardiomyopathy (ATTR‐CM) has a specific pathophysiology, with myocardial stiffening and systolic dysfunction only in advanced stages. We aimed to investigate the response to cardiac resynchronization therapy (CRT) in ATTR‐CM compared with heart failure. Methods In this multicenter, observational study, patients with ATTR‐CM receiving CRT (n=101) were matched to patients without amyloid cardiomyopathy by sex, age, and implantation type (CRT with versus without defibrillator versus conduction system pacing, upgrade versus first implant). We evaluated changes in QRS duration and echocardiographic parameters following CRT implantation and at the most recent available assessments. The study end points were all‐cause death alone or combined with heart failure hospitalization. Results Patients with ATTR‐CM (median age, 76 [interquartile range, 72–83] years, 98% men, left ventricular (LV) ejection fraction 30% [26–33]) showed greater QRS shortening after CRT implantation ( P =0.012), but not after a median of around 1 year ( P =0.152). There were no significant differences in the absolute LV ejection fraction changes immediately after implantation (+7 [+2/+10] versus +3 [0/+9] units; P =0.124), or to the last echo ( P =0.796), which was performed after 1.3 years in patients with ATTR‐CM and 2.9 years in patients without amyloid cardiomyopathy. Patients with ATTR‐CM had a shorter survival than controls ( P <0.001 for both end points). Patients with ATTR‐CM experiencing an early improvement in LV ejection fraction had a longer survival (log‐rank, 4.3; P =0.038). Conclusions Following CRT implantation, patients with ATTR‐CM show QRS narrowing and improvement in LV ejection fraction, not different from patients without amyloid cardiomyopathy. Early favorable LV remodeling seems to be associated with a lower risk of all‐cause death.
Utility of MRI perilesional biopsy in prostate cancer: impact of the Prostate Imaging‐Reporting and Data System and biopsy history
Cannoletta, Donato , Quarta, Leonardo , Pellegrino, Francesco , Scuderi, Simone , Porzi, Maria Elena, Robesti, Daniele , Gandaglia, Giorgio , Karnes, R. Jeffrey , Montorsi, Francesco , Briganti, Alberto , Larcher, Alessandro , Stabile, Armando , Quarta, Leonardo , Pellegrino, Francesco , Scuderi, Simone , Robesti, Daniele , Mazzone, Elio , Karnes, Jeffrey , Montorsi, Francesco , Stabile, Armando , Barletta, Francesco Maria , Scilipoti, Pietro , Longoni, Mattia , Brembilla, Giorgio , COBELLI, Francesco DE , Rouprêt, Morgan

Mayo Clinic

BJU International | October 13, 2025 | Volume: 137 | Issue: 2 | Pages: 282-288

10.1111/bju.70027 | PMID 41077924 Get It

Objective To investigate the diagnostic performance of perilesional biopsies (PLBx) compared to other biopsy strategies, assessing the impact of the Prostate Imaging‐Reporting and Data System (PI‐RADS) score and biopsy history in patients with a visible lesion at multiparametric magnetic resonance imaging of the prostate (mpMRI), as the European Association of Urology guidelines recommend combining MRI‐targeted biopsies (TBx) with PLBx as an alternative to systematic biopsies (SBx) even though evidence is limited. Patients and Methods We relied on a cohort of 2852 patients with PI‐RADS ≥3 lesions undergoing TBx + SBx at three tertiary referral centres. The primary outcome was detection of clinically significant PCa (csPCa) (International Society of Urological Pathology Grade Group [ISUP GG] ≥2) of TBx + PLBx vs TBx + SBx. Results were stratified by PI‐RADS score and biopsy history. The PLBx cores were defined as samples taken from prostate sectors adjacent to the mpMRI lesion. We finally assessed insignificant PCa (insPCa, i.e., ISUP GG 1) detection across biopsy strategies. Differences were assessed using the chi‐square test. Results Detection of csPCa was 48%. Overall, TBx + SBx had a higher csPCa detection rate than TBx + PLBx (50% vs 45%, P = 0.03), particularly in PI‐RADS 3 lesions (26% vs 21%, P = 0.02) and active surveillance (AS) patients (46% vs 40%, P = 0.04). No significant differences were found in PI‐RADS 4 (53% vs 50%, P > 0.1) or PI‐RADS 5 (76% vs 75%, P > 0.1). In the biopsy naïve and previous negative biopsy groups, csPCa detection was similar between strategies ( P > 0.1). Conclusions Overall, TBx + SBx offers the highest detection of csPCa. Even though TBx + PLBx may be considered in PI‐RADS 4–5 lesions to reduce insPCa detection, TBx + SBx remains the preferred strategy for PI‐RADS 3 and AS patients.
Characterization of Spirometric Response to Standard-of-care Treatment in Lung Allograft Recipients With Bronchiolitis Obliterans and the Utility of Spirometric Criteria for Rescue Therapy: Implications for the Design of Risk-stratified Clinical Trials
Hage, Chadi A. , Goldberg, Hilary J. , Patel, Mrunal, Reynolds, John M. , Klesney‐Tait, Julia , Arcasoy, Selim M. , Naik, Chetan , Simone, Nicole De , Usmani, Amena , Girgis, Reda E. , Cordova, Francis , Patil, Jagadish , Morrell, Matthew R. , Lendermon, Elizabeth A. , Huang, Howard J. , Peláez, Andrés, Emtazoo, Amir, Wille, Keith , Chan, Kevin M. , Yung, Gordon , Baz, M., Aryal, Shambhu , Derfler, Mary Clare, Commean, Paul K., Berman, Keith, Прокудин, А. В. , Despotis, George J. , Group, on the behalf of the EPI Study, Baz, Maher, Hachem, Ramsey R. , Byers, Derek E. , Walia, Rajat , Keller, Brian C. , Nunley, David R. , Baz, Maher, Vedantham, Suresh , Atkinson, Andrew , Atkinson, Jeffrey J. , Prokudin, Alexey, McCarthy, John Edward , Group, on the behalf of the EPI Study

Mayo Clinic

Transplantation | October 1, 2025 | Volume: 110 | Issue: 2 | Pages: e481-e491

10.1097/tp.0000000000005515 | PMID 41032890 Get It

Background. The spirometric response to standard-of-care (SOC) immunosuppressive therapy for the management of bronchiolitis obliterans syndrome (BOS) has been sparsely reported in the literature. Data from a Medicare-approved Registry were analyzed to characterize the effectiveness/durability of a wide range of SOC interventions to manage the decline of lung function and to validate the study spirometric criteria for initiation of rescue therapy. Methods. Lung transplant recipients with refractory BOS at 21 US collaborating centers were enrolled in the Registry. Data included both nonspirometric (eg, demographic, Immunosuppressive Regimens for management of BOS) and spirometric parameters (ie, forced expiratory volume in 1 s [FEV 1 ] measurements and derived indices). The utility of study FEV 1 criteria for treatment (ie, statistically significant rate of FEV 1 decline >30 mL/mo) was evaluated by comparing the spirometric course between participants who met or did not meet this criterion. Results. Only 21% of participants treated with SOC therapy had >50% decrease (76 ± 25% decrease) in the rate of FEV 1 decline. Although 51% of participants had a partial response (rate of FEV 1 decline decreased on average 71%), 49% of participants had a substantial increase (mean increase 224%). The FEV 1 criterion for treatment was able to identify 19% of participants (48/258) who achieved durable stabilization (ie, nonsignificant rate of FEV 1 <30 mL/mo) with SOC therapy. Conclusions. Patients with BOS have a widely variable response to SOC therapy. Our findings support the use of FEV 1 rate of decline to assess response to SOC therapy and to ensure appropriate assignment of participants with refractory BOS to rescue therapy treatment cohorts.
An Atomic Force Microscopic analysis of Exosomes derived from Tumor Associated Pluripotent Mesenchymal Stem Cells
Newell, Simone, Armstrong, Erik, Banerjee, Narendra , Cuffee, Jasmine, El-Hashash, Ahmed , Banerjee, Hirendra, Kulkarni, Tanmay , Newell, Simone, Bhattacharya, Santanu , Banerjee, Hirendra

Mayo Clinic

No container title available | September 22, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-7530583/v1 Get It

Abstract Mesenchymal stem cell (MSC)-derived exosomes are recognized as critical mediators within the tumor microenvironment (TME), exerting both pro- and anti-tumorigenic effects depending on contextual factors. These vesicles are also gaining attention for their potential as therapeutic vehicles in regenerative medicine and targeted drug delivery. However, the influence of the TME on the physical characteristics of MSC-derived exosomes remains poorly understood. In this study, we utilized Atomic Force Microscopy (AFM) to investigate the morphological and nanomechanical properties of MSC-derived exosomes under standard and TME-like conditions. AFM imaging in fluid mode preserved the native structure of exosomes and enabled high-resolution analysis of their topography, surface roughness, stiffness, adhesion, and deformation. AFM offers unique advantages in exosome research by enabling label-free, nanoscale analysis of vesicle properties in near-physiological conditions. The ability to detect such subtle but functionally significant changes highlights the relevance of AFM in exosome characterization and quality assessment. Our results revealed that exposure to the TME induces marked changes in exosomal membrane morphology and mechanical behavior, including increased surface heterogeneity, higher stiffness, and altered adhesive interactions. These biophysical alterations may reflect changes in membrane composition and protein or lipid cargo, potentially affecting exosome function, uptake, and therapeutic efficacy. Overall, our findings provide new insights into how the TME modulates MSC exosome biophysics and underscore the utility of AFM-based techniques for advancing the development of exosome-based diagnostics and therapies. This can provide a conceptual framework for future mechanistic and translational studies in this area.
Identification of Surrogate Outcome Biomarkers in Lung Allograft Recipients With Bronchiolitis Obliterans: Implications for Randomized Controlled Trials
Hage, Chadi A. , Goldberg, Hilary J. , Patel, Mrunal, Reynolds, John M. , Klesney‐Tait, Julia , Arcasoy, Selim M. , Naik, Chetan , Simone, Nicole De , Usmani, Amena , Girgis, Reda E. , Cordova, Francis , Patil, Jagadish , Morrell, Matthew R. , Lendermon, Elizabeth A. , Huang, Howard J. , Peláez, Andrés, Emtazoo, Amir, Wille, Keith , Chan, Kevin M. , Yung, Gordon , Baz, M., Aryal, Shambhu , Derfler, Mary Clare, Commean, Paul K., Berman, Keith, Прокудин, А. В. , Despotis, George J. , Group, The EPI Study, Baz, Maher, Byers, Derek E. , Hachem, Ramsey R. , Walia, Rajat , Keller, Brian C. , Nunley, David R. , Baz, Maher, Vedantham, Suresh , Atkinson, Andrew , Atkinson, Jeffrey J. , Prokudin, Alexey, McCarthy, John Edward , Group, The EPI Study

Mayo Clinic

Transplantation Direct | September 19, 2025 | Volume: 11 | Issue: 10 | Pages: e1857

10.1097/txd.0000000000001857 | PMID 40989076 Get It

BACKGROUND. We developed a prospective, multicenter “registry” to evaluate the effect of extracorporeal photopheresis for lung transplant recipients who develop chronic lung allograft dysfunction (CLAD) with the bronchiolitis obliterans syndrome (BOS) phenotype (CLAD/BOS) and who are refractory to conventional standard-of-care therapy. METHODS. Data from 258 lung transplant recipients enrolled in the Registry between April 2015 and April 2022 were included in this analysis. All recorded parameters (eg, demographics), including forced expiratory volume in 1 s (FEV1) measurements and indices (FEV1% baseline, FEV1 rate of decline) at several time periods, were included in multivariate linear/logistic and Kaplan-Meier analyses to evaluate potential associations with survival. RESULTS. Mortality at 6 and 12 mo after CLAD/BOS diagnosis was 5% and 14%, whereas mortality at 6 and 12 mo after enrollment was 15% and 26%, respectively. The primary cause of death in the cohort was respiratory failure or graft failure (74%). Rate of FEV1 decline (log) at enrollment was independently associated with survival (log days) from CLAD/BOS diagnosis and enrollment (r = 0.55 and r = 0.3, respectively). The rates of FEV1 decline among survivors were lower (–77 ± 89 mL/mo) compared with nonsurvivors (–148 ± 155 mL/mo) at 6 mo after enrollment (P = 0.0001). CONCLUSIONS. The rate of FEV1 decline quantified using at least 5 FEV1 measurements is a robust surrogate outcome. We plan to use these findings to revise our randomized controlled trial to facilitate risk adjustment using FEV1 rate of decline strata at enrollment and as a scientifically valid surrogate for outcome.
A structured training curriculum for robot‐assisted radical nephroureterectomy: a Delphi consensus study
Sayyid, Rashid K. , Wu, Zhenjie , Antonelli, Alessandro , Guo, Shengjie , Hung, Andrew J. , Ma, Lulin , Margulis, Vitaly , Mehrazin, Reza , Porter, James , Potretzke, Aaron M. , Seisen, Thomas , Stein, Robert J. , Wang, Long , Wu, Jitao, Xylinas, Évanguelos , Djaladat, Hooman , Sayyid, Rashid K , Wu, Zhenjie , Abdollah, Firas , Antonelli, Alessandro , Ma, Lulin , Margulis, Vitaly , Matin, Surena F. , Potretzke, Aaron, Simone, Giuseppe , Wang, Long , Autorino, Riccardo , Djaladat, Hooman , Ghoreifi, Alireza , Moghaddam, Farshad Sheybaee , Ghoreifi, Alireza , Abdollah, Firas , Eun, Daniel , Ma, Lulin , Pradère, Benjamin , Rouprêt, Morgan , Shariat, Shahrokh F. , Simone, Giuseppe , Yao, Lin Xin , Zargar, Homayoun S. , Autorino, Riccardo , Cacciamani, Giovanni

Mayo Clinic

BJU International | September 17, 2025 | Volume: 136 | Issue: 6 | Pages: 1114-1120

10.1111/bju.70000 | PMID 40960222 Get It

Objectives To develop an internationally validated, structured robot‐assisted radical nephroureterectomy (RARNU) training programme through expert consensus. Materials and Methods A RARNU‐specific questionnaire was developed/adapted from previously published, validated questionnaires for robot‐assisted urological procedures. This included five key domains and 11 surgical steps. In all, 30 upper tract urothelial carcinoma experts were invited to participate. A two‐stage modified Delphi approach was employed. Consensus was defined as ≥80% agreement. Modifications and additional statements were proposed during the second round following qualitative/quantitative feedback from the initial round. Results Response rates for the first and second Delphi rounds were 80% (24/30) and 92% (22/24), respectively. All agreed that adoption of a standardised training curriculum can improve clinical outcomes during the RARNU learning curve. There was ≥92% agreement on all proposed RARNU steps. Five RARNU clinical modules of increasing complexity were defined using individual step difficulty and number of prior RARNU cases required, with ≥96% agreement among respondents. Respondents unanimously agreed that the final assessment should be based on a procedure‐specific scale focusing on the hilar dissection, ureteric dissection, and bladder cuff excision steps. No consensus was reached for the annual minimum RARNU volume required for eligibility as a RARNU curriculum host centre. Conclusion This is the first structured training curriculum for RARNU using international expert consensus. This will help guide surgical educators and trainees toward independent completion of a full RARNU.
Comparative Clinical and Imaging Outcomes of Particulated Juvenile Articular Cartilage Implantation in Shouldered and Unshouldered Patellar Cartilage Lesions With Concomitant Stabilization at 2-Year Follow-up
Davie, Ryann , Ammerman, Brittany , Propp, Bennett E. , Marmor, William A. , Pahapill, Natalie , Kingston, Kiera, Gruber, Simone , Burge, Alissa J. , Wimberly, Audrey , Nguyen, Joseph , Marigi, Erick , Marmor, William , Nguyen, Joseph , Dennis, Elizabeth , Marigi, Erick M. , Stein, Beth E. Shubin

Mayo Clinic

Orthopaedic Journal of Sports Medicine | September 17, 2025 | Volume: 13 | Issue: 9 | Pages: No page available

10.1177/23259671251369018 | PMID 40980560 Get It

Background: Particulated juvenile articular cartilage (PJAC) implantation has demonstrated promising early results in the treatment of symptomatic articular cartilage defects of the patella. However, some uncertainty exists regarding the stability of this cell-based technique in lesions that are not well contained or shouldered. Purpose: To compare clinical and magnetic resonance imaging (MRI) outcomes of PJAC treatment in shouldered versus unshouldered full-thickness cartilage defects of the patella. Study Design: Cohort study; Level of evidence, 3. Methods: A retrospective review of prospectively collected data from an institutional knee registry was conducted to identify patients treated with PJAC for full-thickness symptomatic patellar cartilage lesion between January 2009 and August 2017. Cartilage defects were graded arthroscopically according to the Outerbridge classification and characterized as shouldered or unshouldered. For the primary outcome, postoperative MRI studies were read by a musculoskeletal fellowship-trained radiologist who characterized the percentage of fill based on both coronal and sagittal images. Patient-reported outcome measures (PROMs) were obtained at baseline and 2-year follow-up. MRI and PROM results were compared between the shouldered and unshouldered cohorts. Results: A total of 64 knees in 60 patients (mean age, 26.3 ± 7.6 years) were identified, of which 62 (97%) knees underwent a concomitant patellar stabilization or offloading procedure. There were 32 (50%) shouldered and 32 (50%) unshouldered defects. On postoperative MRI, 68.8% of shouldered lesions demonstrated 67% to 100% fill, compared with 59.4% of unshouldered lesions; 12.5% of shouldered lesions and 15.6% of unshouldered lesions demonstrated 34% to 66% fill; and 18.8% of shouldered lesions and 25.0% of unshouldered lesions demonstrated 0% to 33% fill ( P = .604). At 2 years, significant improvements were observed in Knee Injury and Osteoarthritis Outcome Score (KOOS) Quality of Life (QOL) (23.1 to 65.3; P < .001), International Knee Documentation Committee (IKDC) (41.2 to 76.0; P < .001), KOOS Physical Function Shortform (PS) (34.8 to 13.9; P < .001), Kujala (52.0 to 87.5; P < .001), 12-Item Short Form Survey (SF-12) Physical Health (39.5 to 51.5; P < .001), Veterans Rand 12 Item Health Survey (VR-12) Physical Health (40.7 to 52.8; P < .001), Veterans Rand 6D (0.66 to 0.79; P < .001), SF-12 Mental Health (48.9 to 53.4; P = .015), and VR-12 Mental Health (49.4 to 54.0; P = .019) values. No significant change was observed in Pediatric Functional Activity Brief Scale score (9.1 to 10.3; P = .384). All PROMs were equivalent between shouldered and unshouldered defects at the 2-year follow-up ( P = .318-.980). There was a greater improvement in both KOOS PS (27.2 vs 10.7; P = .015) and Kujala (44.3 vs 26.9; P = .039) values from baseline to the 2-year follow-up in the shouldered group. Conclusion: PJAC implantation with concomitant patellar stabilization led to significantly improved PROMs for both shouldered and unshouldered patellar cartilage lesions over time. Additionally, minimal differences were observed between shouldered and unshouldered defects treated with PJAC at the 2-year follow-up.
Repeat-associated ataxias in a German patient cohort analysed by targeted parallel long-read sequencing
Erdmann, Hannes , Schaub, Annalisa , Lucas, Morghan C. , Scholz, Veronika , Benet‐Pagès, Anna , Dineiger, Christine, Mayer, Veronika, Buren, Inga Van , Breithausen, Eva, Akbari, Karl, Sauer, Mayra , Krakowsky, Rosanna , Schnabel, Franziska , Dunker, Konstanze, Fabritius, Lena, Gerb, Johannes , Grabova, Denis , Möhwald, Ken , Näher, Marius, Steinmetz, Karoline , Thiessen, Franziska, Jäck, Alexander , Schreyer, Isolde, Mämecke, Larissa, Wilfling, Sibylle, Wunderlich, Gilbert , Hellenbroich, Yorck, Muhle, Kirsten, Claus, Inga, Klopstock, Thomas, Strupp, Michael, Xiong, Chengjie , Huppert, Doreen , Becker‐Bense, Sandra , Filippopulos, Filipp , Kilpert, Fabian , Kaya, Sabine, Schöberl, Florian, Neuhann, Teresa , Holinski‐Feder, Elke , Zwergal, Andreas , Abicht, Angela, Cordts, Isabell , Gerb, Johannes , Brenner, David , Xiong, Chengjie , Kilpert, Fabian , Depienne, Christel , Zwergal, Andreas , Becker, Kerstin , Mayer, Veronika, Akbari, Karl, Schneider, Christine B. , Thiessen, Franziska, Schneider-Gold, Christiane , Zittel, Simone , Petersen, Christina, Huchtemann, Tessa , Höglinger, Günter U. , Leitão, Elsa , Depienne, Christel , Abicht, Angela

Mayo Clinic

Brain | September 1, 2025 | Volume: 149 | Issue: 3 | Pages: 993-1006

10.1093/brain/awaf318 | PMID 40898875 Get It

Abstract Hereditary adult-onset ataxias are a heterogeneous group of phenotypically overlapping conditions, often caused by pathogenic expansions of short tandem repeats. Currently, 18 repeat disorders with a core phenotype of adult-onset ataxia are known. Diagnosis typically relies on sequential PCR-based methods, which are labour-intensive and lack precision. Long-read sequencing (LRS) has the potential to overcome these limitations and is currently implemented and validated in clinical genetics. Using clinical nanopore Cas9-targeted sequencing (Clin-CATS) for parallel in-depth repeat analysis, we evaluated a diagnostic cohort of 513 adult-onset ataxia patients, determining frequencies of all known repeat-associated ataxias except Spinocerebellar ataxia 4 (SCA4), as well as the carrier frequencies for autosomal-recessive disorders, RFC1 spectrum disorder and Friedreich’s ataxia (FRDA). Additionally, phenotypes of patients with established genetic diagnoses were characterized, especially those of patients living with RFC1 spectrum disorder and SCA27B. Repeat-associated ataxias were confirmed in 33.3% of cases, including rare ataxias, such as SCA10, SCA36 and SCA37, alongside as the most prevalent conditions SCA27B and RFC1 spectrum disorder. Potentially pathogenic expansions in FGF14 were identified in an additional 4.7% of patients. Testing of another 347 patients for ZFHX3 expansions linked to SCA4 did not identify any cases. Dual diagnoses were frequent, occurring in 6.4% of patients with repeat-associated ataxia. We confirmed a high RFC1 spectrum disorder carrier frequency (7.2%) and reclassified certain FXN expansions as likely non-pathogenic, resulting in a lower than estimated carrier frequency for FRDA of 0.8%. We also identified novel repeat configurations in several loci and illustrated the high heterogeneity of repeat expansions in RFC1, highlighting it as a potential source of false results when using PCR-based methods. This study underscores the diagnostic advantages of LRS for comprehensive repeat analysis and recommends its adoption as a standard in clinical genetics, replacing Southern blot and PCR-based approaches. Furthermore, based on our findings in a large patient cohort a re-evaluation of existing phenotype-genotype correlations is recommended as well as evaluating additional parameters alongside the repeat length to improve diagnostic precision of repeat analysis.
Monitoring cardiogenic shock: echodynamics vs. pulmonary artery catheter Viewpoints from two leading experts
Boretto, Paolo , Jentzer, Jacob C. , Frea, Simone , Pöss, Janine, Jentzer, Jacob C , Frea, Simone , Galluzzo, Alessandro

Mayo Clinic

European Heart Journal: Acute Cardiovascular Care | August 4, 2025 | Volume: 14 | Issue: 9 | Pages: 576-578

10.1093/ehjacc/zuaf100 | PMID 40758819 Get It

NRG Oncology Liver Proton SBRT and Hypofractionated Radiation Therapy: Current Treatment Technical Assessment and Practice Patterns
Kang, Minglei , Taylor, Paige A. , Shen, Jiajian , Saini, Jatinder, Hong, Theodore S. , Liu, Wei , Xiao, Ying , Simone, Charles B. , Lin, Liyong , Liu, Wei , Xiao, Ying , Simone, Charles B , Lin, Liyong , Taylor, Paige , Shen, Jiajian , Zhou, Jun , Higgins, Kristin Ann

Mayo Clinic

Cancers | July 17, 2025 | Volume: 17 | Issue: 14 | Pages: 2369

10.3390/cancers17142369 | PMID 40723252 Get It

Background/Objectives: Proton therapy delivers highly conformal doses to the target area without producing an exit dose, minimizing cumulative doses to healthy liver tissue. This study aims to evaluate current practices, challenges, and variations in the implementation of proton stereotactic body radiation therapy (SBRT) and hypofractionated therapy for liver malignancies, with the goal of providing a technical assessment to promote broader adoption and support future clinical trials. Methods and Materials: An extensive survey was conducted by NRG Oncology across North American proton treatment centers to assess the current practices of proton liver SBRT and hypofractionated therapy. The survey focused on key aspects, including patient selection, prescription and normal tissue constraints, simulation and motion management, treatment planning, quality assurance (QA), treatment delivery, and the use of image-guided radiation therapy (IGRT). Results: This survey captures the current practice patterns and status of proton SBRT and hypofractionated therapy in liver cancer treatment. Proton therapy is increasingly preferred for treating inoperable liver malignancies due to its ability to minimize healthy tissue exposure. However, the precision required for proton therapy presents challenges, particularly in managing uncertainties and target motion during high-dose fractions and short treatment courses. Survey findings revealed significant variability in clinical practices across centers, highlighting differences in motion management, dose fractionation schedules, and QA protocols. Conclusion: Proton SBRT and hypofractionated therapy offer significant potential for treating liver malignancies. A comprehensive approach involving precise patient selection, treatment planning, and QA is essential for ensuring safety and effectiveness. This survey provides valuable insights into current practices and challenges, offering a foundation for technical recommendations to optimize the use of proton therapy and guide future clinical trials.